It was the second straight sizable increase, suggesting that U.S. drug makers with Irish manufacturing hubs like Indianapolis-based Eli Lilly and Co. could be stockpiling products ahead of any tariffs ...

Eli Lilly's foray into telehealth shows the emerging importance virtual care platforms are playing in the rising popularity ...

Eisai/Biogen’s Leqembi (lecanemab) was fully approved in the US in July 2023, and Eli Lilly’s Kisunla (donanemab) in July ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Blarcamesine is a sigma 1 receptor agonist which targets Alzheimer's pathology upstream of amyloid and tau pathology.

Buoyed by new results from a phase 1b/2a trial, Roche has said it plans to start a phase 3 programme for an Alzheimer's ...

The trip will include a mix of rail travel and immersive experiences across 14 countries: France, Austria, Switzerland, ...

Eli Lilly's Alzheimer's treatment is approved for use in the U.S. but the European Medicines Agency recommended against the approval of the drug on Thursday.

Altria has an impressive streak of raising its dividend for 55 consecutive years. Eli Lilly's current streak only goes back ...

Eli Lilly is suing two pharmacies for compounding Zepbound and Mounjaro, claiming the companies are skirting the Food and Drug Administration's ban on the practice and luring people away from ...

This is roughly $800 more than the list price Eli Lilly & Co. charges for its drug, and includes a Hims membership, unlimited consultations with a provider and treatment support, the spokesperson ...